SEC filing · 8-K

Faeth Therapeutics, Inc.: Executive or director change

Faeth Therapeutics appointed company co-founder Dr. Karen Vousden to its Board of Directors.

Filed September 17, 2026

Positive for the company

What happened

On September 11, 2026, the Board increased its size from five to six directors and appointed Dr. Karen Vousden as a Class II director effective immediately.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Faeth Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.